{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:05:25Z","timestamp":1789635925370,"version":"4.0.0"},"reference-count":30,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Venous thromboembolism (VTE) in athletes presents a unique clinical challenge that contradicts the traditional perception of athletes as low-risk individuals. While regular exercise mitigates cardiovascular risk and improves venous flow through frequent mobilization, injuries, inappropriate mechanics of participation, comorbid medical conditions, recreational utilization of performance-enhancing medication, and underlying thrombophilia all create unique circumstances for thrombosis in this patient population. Individual consideration of anticoagulant agent use, duration of treatment, and pauses in treatment depend on underlying bleeding and thrombosis risk and level of activity and lifestyle for each patient. Continuation of anticoagulation after return to participation in sports also requires thorough risk\u2013benefit assessment factoring in overall health, and hinges partially on the ability to reverse the effect of anticoagulation in dire situations. Guidance about continuation of a particular sport if long-term anticoagulation is needed depends on shared decision-making about morbidity and quality of life. Adjunct methods to prevent further thrombosis and manage post-thrombotic syndrome are also important for athletic longevity. There is a growing body of literature regarding evaluation and management of athletes with thrombosis, and the authors aim to summarize recommendations as they apply to pediatric and adult athletes. However, it is noted that continued study of this topic is needed to create more generalized recommendations rather than considerations for individual patient management, as discussed within this article.<\/jats:p>","DOI":"10.3390\/jcm15187213","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:03:17Z","timestamp":1789632197000},"page":"7213","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Anticoagulation in Athletes"],"prefix":"10.3390","volume":"15","author":[{"given":"Pranavi","family":"Bavishi","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology, Northwestern Medicine, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Raghavendran","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1055\/s-0038-1673625","article-title":"Acquired and Genetic Thrombotic Risk Factors in the Athlete","volume":"44","author":"Zadow","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_2","first-page":"181","article-title":"Sport and Venous Thromboembolism\u2014Site, Accompanying Features, Symptoms, and Diagnosis","volume":"118","author":"Hilberg","year":"2021","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation","volume":"83","author":"Joglar","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Miele, C., Mennitti, C., Gentile, A., Veneruso, I., Scarano, C., Vastola, A., La Monica, I., Uomo, F., Iafusco, F., and Capasso, F. (2024). Thrombosis and Thrombotic Risk in Athletes. J. Clin. Med., 13.","DOI":"10.3390\/jcm13164881"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(20)32658-1","article-title":"Venous Thromboembolism","volume":"398","author":"Khan","year":"2021","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1016\/j.hrthm.2024.05.018","article-title":"2024 HRS Expert Consensus Statement on Arrhythmias in the Athlete","volume":"21","author":"Lampert","year":"2024","journal-title":"Heart Rhythm"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1161\/CIRCULATIONAHA.118.039461","article-title":"Long-Term Incidence of Atrial Fibrillation and Stroke Among Cross-Country Skiers","volume":"140","author":"Svedberg","year":"2019","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.rpth.2025.103208","article-title":"Thrombotic complications of glucocorticoids and anabolic steroids","volume":"9","author":"Gurumurthy","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1055\/s-0031-1297371","article-title":"Doping and thrombosis in sports","volume":"37","author":"Lippi","year":"2011","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2020.17272","article-title":"Diagnosis and Treatment of Lower Extremity Venous Thromboembolism","volume":"324","author":"Chopard","year":"2020","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2020.07.070","article-title":"Antithrombotic Management of Venous Thromboembolism","volume":"76","author":"Renner","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1055\/a-2632-3197","article-title":"Management of Anticoagulant Therapy in Athletes and Sportspeople","volume":"125","author":"Campello","year":"2025","journal-title":"Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jvs.2020.05.048","article-title":"Evaluation and Treatment of Thoracic Outlet Syndrome During the Global Pandemic Due to SARS-CoV-2 and COVID-19","volume":"72","author":"Ohman","year":"2020","journal-title":"J. Vasc. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMcp1008740","article-title":"Deep-Vein Thrombosis of the Upper Extremities","volume":"364","author":"Kucher","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"151125","DOI":"10.1016\/j.sempedsurg.2021.151125","article-title":"Venous Thoracic Outlet Syndrome and Paget\u2013Schroetter Syndrome","volume":"30","author":"Modi","year":"2021","journal-title":"Semin. Pediatr. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jvs.2022.11.053","article-title":"Venographic Classification and Long-Term Surgical Treatment Outcomes for Axillary-Subclavian Vein Thrombosis Due to Venous Thoracic Outlet Syndrome","volume":"77","author":"Dadashzadeh","year":"2023","journal-title":"J. Vasc. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s12178-020-09643-x","article-title":"Thoracic Outlet Syndrome in the Overhead Athlete","volume":"13","author":"Ohman","year":"2020","journal-title":"Curr. Rev. Musculoskelet. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/jdv.19523","article-title":"Effect of Exercise After a Deep Venous Thrombosis","volume":"38","author":"Rook","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1055\/s-0038-1673690","article-title":"Treatment of Venous Thromboembolism in Elite Athletes","volume":"44","author":"Nazha","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_21","unstructured":"American College of Cardiology (2026). Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement. J. Am. Coll. Cardiol., Epub ahead of printing."},{"key":"ref_22","unstructured":"European Heart Rhythm Association (2021). Practical guide on the use of non-vitamin K antagonist oral anticoagulants: Pharmacokinetic characteristics and dosing considerations. Europace, 23, 1612\u20131676."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/blood-2015-06-651539","article-title":"Improving Evidence on Anticoagulant Therapies for Venous Thromboembolism in Children","volume":"126","author":"Goldenberg","year":"2015","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"E351","DOI":"10.1161\/CIR.0000000000001285","article-title":"2024 AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery","volume":"150","author":"Thompson","year":"2024","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sabouret, P., Atar, D., Bernardi, M., and Giamundo, D.M. (2026). Main Lessons of the Recent Andexanet Withdrawal. Cardiology, Epub ahead of printing.","DOI":"10.1159\/000551185"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for Dabigatran Reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/asheducation-2018.1.412","article-title":"Elite Athletes and Anticoagulant Therapy: An Intermittent Dosing Strategy","volume":"2018","author":"Moll","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2021.23182","article-title":"Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months in Patients Younger Than 21 Years with Provoked Venous Thromboembolism","volume":"327","author":"Goldenberg","year":"2022","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood.2022018966","article-title":"How I Treat Pediatric Venous Thromboembolism in the DOAC Era","volume":"143","author":"Bhat","year":"2024","journal-title":"Blood"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7213\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:42:12Z","timestamp":1789634532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":30,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15187213"],"URL":"https:\/\/doi.org\/10.3390\/jcm15187213","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}